Xanthus Life Sciences Presents In Vitro Data Demonstrating That Symadex Is A Potent And Selective Inhibitor Of FLT3

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today presented data from a study in which Symadex(TM) (C-1311) was identified as a potent, selective inhibitor of the receptor tyrosine kinase (RTK), FLT3. The presentation was made in a poster session at the 2006 American Association for Cancer Research (AACR) International Conference on Molecular Diagnostics in Cancer Therapeutic Development meeting in Chicago, IL.